Related Experiment Video
Updated: Apr 26, 2026

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
CFTR potentiators: not an open and shut case
1Cincinnati Children's Hospital Medical Center and the University of Cincinnati, Cincinnati, OH 45229, USA.
New cystic fibrosis (CF) drug insights reveal both benefits and drawbacks, prompting a reevaluation of therapeutic discovery and development strategies for CF patients with common mutations.
Area of Science:
- Pharmacology
- Genetics
- Medical Research
Background:
- Cystic fibrosis (CF) affects multiple organs due to genetic mutations.
- Targeted therapies aim to correct the underlying protein defects in CF.
Purpose of the Study:
- To analyze the multifaceted effects of current CF drugs.
- To explore challenges in translating CF therapeutic discoveries into clinical practice.
Main Methods:
- Review of recent studies on CF therapeutics.
- Analysis of clinical trial outcomes and patient responses.
Main Results:
- Drugs show positive impacts on CFTR function but also present adverse effects.
- Variability in patient response highlights the need for personalized medicine approaches.
Conclusions:
- Current CF treatments offer significant benefits but require careful management.
- Further research is essential to optimize therapeutic strategies and address unmet needs in CF care.
More Related Videos
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
06:59A Fluorescence-Based Assay of Membrane Potential for High-Throughput Functional Study of Two Endogenous Ion Channels in Two Epithelial Cell Lines
Published on: June 22, 2022
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
GPCRs Regulate Adenylyl Cylase Activity
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Cystic Fibrosis: Management
Sinus disease and chronic...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Direct-Acting Cholinergic Agonists: Therapeutic Uses